GILD logo

Gilead Sciences, Inc.

GILD
Healthcare|Drug Manufacturers - General|US
$166.89
-0.68 (-0.41%)
DCF Value
$137.19
Cash / Share
$5.18

Clinical Trials (536)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT07476339
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE
HIV -1 Infection, HIV (Human Immunodeficiency Virus)
P4
Recruiting200Open-labelBictegravir, emtricitabine, and tenofovir alafenamide
NCT07210125
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
HIV
P4
Active75Open-labelLenacapavir long-acting
NCT06964113
A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
Ulcerative Colitis
P4
Active94Open-labelFilgotinib Maleate
NCT05140941
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
Hepatitis C, Chronic, Pregnancy; Infection
P4
Active100Open-labelSofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
NCT06374758
Accelerated ART Initiation for PWHIV Who Are Out of Care
HIV Infections, ART
P4
Active120Open-labelbictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
NCT05633654
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple Negative Breast Cancer
P3
Recruiting1,514RCT, Open-labelSacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine
NCT05814432
Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS
Disseminated Histoplasma Capsulatum Infection, AIDS and Infections
P3
Recruiting279RCT, Open-labelSingle high dose of liposomal amphotericin B, L-AmB standard dose
NCT05502237
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
P3
Active1,021RCT, Open-labelZimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
NCT06413498
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma
P3
Active452RCT, Open-labelAnitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib
NCT05552001
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
Triple Negative Breast Cancer, Metastatic Breast Cancer
P3
Active96Open-labelSacituzumab govitecan
NCT03301506
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
Primary Biliary Cirrhosis
P3
Active340Open-labelSeladelpar 5 mg Capsule, Seladelpar 10 mg Capsule
NCT05371093
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
Relapsed/Refractory Follicular Lymphoma
P3
Active231RCT, Open-labelAxicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab, Doxorubicin, Vincristine, Prednisone, Bendamustine
NCT05382299
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Triple Negative Breast Cancer, PD-L1 Negative
P3
Active623RCT, Open-labelSacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin
NCT05605899
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
High-risk Large B-cell Lymphoma (LBCL)
P3
Active300RCT, Open-labelAxicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Etoposide, Rituximab, Doxorubicin, Vincristine, Prednisone
NCT06630299
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
HIV-1-Infection
P3
Active600RCT, Open-labelISL/LEN, Antiretroviral Combinations
NCT05089734
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
P3
Active603RCT, Open-labelSacituzumab Govitecan-hziy (SG), Docetaxel
NCT07682961
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
HIV Infections
P3
Recruiting590RCT, Open-labelLenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine
NCT02881320
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1
HIV-1 Infection
P2P3
Active177Open-labelB/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS), B/F/TAF (TOS), B/F/TAF (TOS), B/F/TAF (TOS)
NCT05840211
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
P3
Active654RCT, Open-labelSacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine
NCT06801834
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
P3
Recruiting695RCT, Open-labelSacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available)
NCT05382286
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Triple Negative Breast Cancer, PD-L1 Positive
P3
Active443RCT, Open-labelSacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin
NCT06486441
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Endometrial Cancer
P3
Active640RCT, Open-labelSacituzumab govitecan-hziy, Doxorubicin, Paclitaxel
NCT04595565
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
HER2-negative Breast Cancer, Triple Negative Breast Cancer
P3
Active1,332RCT, Open-labelCapecitabine, Carboplatin, Cisplatin, Sacituzumab govitecan
NCT06544733
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
HIV-1-Infection
P2P3
Active675RCT, Double-blindLepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC
NCT06333808
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
HIV-1-infection
P3
Active577RCT, Double-blindBictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN FDC, Placebo to match Lenacapavir
NCT05396885
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Multiple Myeloma
P2
Active136Open-labelanitocabtagene-autoleucel
NCT04986579
Scalp Cooling in MBC
Metastatic Breast Cancer, Chemotherapy-induced Alopecia
P2
Recruiting120Open-labelEribulin, Sacituzumab govitecan, Trastuzumab deruxtecan
NCT05633667
Study of Novel Treatment Combinations in Patients With Lung Cancer
Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer
P2
Active192RCT, Open-labelZimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab
NCT05676931
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
Advanced Non-Small Cell Lung Cancer
P2
Active400RCT, Open-labelDomvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet
NCT06048133
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Biliary Tract Carcinoma, Cholangiocarcinoma
P2
Active33Open-labelGemcitabine, Cisplatin, Zimberelimab, Quemliclustat
NCT05327530
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
Locally Advanced or Metastatic Urothelial Carcinoma
P2
Active256RCT, Open-labelAvelumab, Sacituzumab Govitecan (SG), M6223, NKTR-255, JB100
NCT06727565
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
Head and Neck Squamous Cell Carcinoma
P2
Active39RCT, Open-labelDomvanalimab, Zimberelimab, Paclitaxel, Carboplatin
NCT06657222
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Advanced Solid Tumors, HNSCC
P1P2
Recruiting250RCT, Open-labelTUB-030
NCT03971409
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Stage III Breast Cancer, Stage IIIA Breast Cancer
P2
Active145RCT, Open-labelAnti-OX40 Antibody PF-04518600, Avelumab, Binimetinib, Utomilumab, Liposomal Doxorubicin, Sacituzumab Govitecan
NCT06477419
A Study of Sacituzumab Govitecan in People With Mesothelioma
Mesothelioma, Mesotheliomas Pleural
P2
Recruiting33Open-labelSacituzumab govitecan-hziy
NCT06248515
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Thymoma, Thymic Carcinoma
P2
Recruiting18Open-labelSacituzumab govitecan-hziy
NCT07736937
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
Ovarian Cancer
P1P2
Recruiting72Open-labelTUB-040 + Carbo + BEV
NCT07841977
Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis
Primary Biliary Cholangitis
P2
Recruiting132RCT, Double-blindSeladelpar, PTM Seladelpar, Cilofexor Dose B, PTM Cilofexor Dose A, PTM Cilofexor Dose B, Cilofexor Dose A
NCT05884320
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
Gland, Salivary Gland Cancers
P2
Active63RCT, Open-labelSacituzumab Govitecan
NCT06923826
Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)
Salivary Gland Cancer, Thyroid Cancer
P2
Recruiting32Open-labelSacituzumab govitecan
NCT06029972
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
P2
Active176RCT, Double-blindTilpisertib Fosmecarbil, Placebo
NCT06401824
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
NSCLC Stage IV, Brain Metastases, Adult
P2
Recruiting25Open-labelSacituzumab Govitecan-Hziy 180 MG plus bevacizumab
NCT03547973
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Metastatic Urothelial Cancer
P2
Active502Open-labelSacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Avelumab, Zimberelimab, Carboplatin, Gemcitabine, Domvanalimab, Enfortumab Vedotin
NCT04989803
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Relapsed and/or Refractory B-cell Lymphoma
P1P2
Active247Open-labelCyclophosphamide, Fludarabine, KITE-363, KITE-753
NCT06238921
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
Breast Cancer, Triple Negative Breast Cancer
P1P2
Recruiting31Open-labelZimberelimab, Sacituzumab govitecan
NCT06303505
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ovarian Cancer, Non-small Cell Lung Cancer
P1P2
Recruiting334Open-labelTUB-040, Bevacizumab
NCT06612203
Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer
Advanced Breast Cancer
P1P2
Active76Open-labelDebio 0123 and Sacituzumab govitecan
NCT05186974
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
P2
Active193RCT, Open-labelSacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin, Cisplatin
NCT02932150
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
Chronic Hepatitis B
P2
Active150RCT, Double-blindTAF, Placebo
NCT04448886
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Invasive Breast Cancer, Metastatic Breast Cancer
P2
Active110RCT, Open-labelPembrolizumab, Sacituzumab Govitecan
NCT07546812
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
HER2-negative, Gastroesophageal Junction
P2
Recruiting120RCT, Open-labelDenikitug, Nivolumab, Ramucirumab, Paclitaxel
NCT06665178
Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
Breast Cancer
P2
Recruiting20Open-labelSacituzumab Govitecan
NCT07645287
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
HIV-1-infection
P2
Recruiting175RCT, Open-labelGS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
NCT05457010
Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
P1
Active24Open-labelSPRX002, ARC-T Cells, Cyclophosphamide, Fludarabine
NCT05833867
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
P1
Recruiting20Open-labelSacituzumab govitecan
NCT04155749
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Relapsed and Refractory Multiple Myeloma
P1
Active40Open-labelanitocabtagene-autoleucel
NCT06167317
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Advanced Solid Tumors
P1
Recruiting278Open-labelGS-0201, Sacituzumab Govitecan
NCT07128303
Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors
Advanced Solid Tumor
P1
Recruiting476Open-labelGS-5319, Carboplatin, Pemetrexed, Pembrolizumab
NCT06065371
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Gastrointestinal Cancer
P1
Recruiting20Open-labelCapecitabine, Sacituzumab govetican
NCT05840224
Study of GS-4528 in Adults With Solid Tumors
Solid Tumor
P1
Active182Open-labelGS-4528, Zimberelimab
NCT06082960
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Solid Tumors
P1
Active45Open-labelGS-9911, Zimberelimab
NCT00404989
Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.
HIV Infections, Hepatitis B
Recruiting24,258——
NCT03275311
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
Metastatic Breast Cancer
Recruiting42,000——
NCT03577197
Southeast Netherlands Advanced Metastatic Breast Cancer Registry
Advanced Breast Cancer, Metastatic Breast Cancer
Recruiting7,000——
NCT02622581
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic
Recruiting14,500——
NCT07652359
Empowering Monterey Bay Residents for Activated, Collaborative, and Equitable Care
Shared Decision-Making, Quality of Life
N/A
Recruiting138RCT, Double-blind—
NCT06889805
HDV Screening Study
Hepatitis D Virus Infection
Recruiting300——
NCT04956445
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
Covid19
Recruiting2,000——
NCT07238114
Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors
Liver Cirrhosis, Viral Pneumonia
Active450——
NCT06774027
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma
Recruiting100—Non-Investigational Antibody-Drug Conjugates (ADC)
NCT07473778
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
HIV Infections
Recruiting3,000—Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet
NCT05688592
Usefulness of PET-CT for Invasive Fungal Infection
Invasive Fungal Infections
Recruiting224——
NCT01961232
Trans-pulmonary Biomarkers in Pulmonary Hypertension
Pulmonary Hypertension
Active100——
NCT06353295
Community-based, Peer-delivered PrEP for Female Sex Workers in Rural Uganda: The Peers for PrEP (P4P) Study
HIV/AIDS
N/A
Active140Open-label—
NCT03502005
Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1
Human Immunodeficiency Virus
P4
Completed100Open-labelbictegravir/emtricitabine/tenofovir alafenamide
NCT02691728
Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease
Chronic Hepatitis C
P4
Unknown40Open-labelLDV/SOF FDC
NCT03044964
Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)
Angina
P4
Unknown40RCT, Double-blindRanolazine, Placebo
NCT01641367
A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
HIV-1 Infection
P4
Completed545RCT, Open-labelDarunavir, Etravirine, Emtricitabine/tenofovir disoproxil fumarate, Raltegravir, Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs), Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available
NCT02800655
Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy
HIV
P4
Unknown100Open-label—
NCT04650269
Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program
Harm Reduction, HIV Infections
P4
Completed27Open-labelBiktarvy 50Mg-200Mg-25Mg Tablet
NCT03717129
Analysis of Crushed and Whole Tablet Genvoya
Healthy Volunteers
P4
Completed12Open-labelGenvoya Oral dose, Genvoya Crushed Dose
NCT00389402
BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes
HIV Infections
P4
Completed120RCT, Open-labelsaquinavir/ritonavir, atazanavir/ritonavir
NCT03309592
Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension
Portopulmonary Hypertension, Pulmonary Hypertension
P4
Withdrawn—Open-labelAmbrisentan Pill, Tadalafil Pill
NCT00697944
Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients
Sepsis, Candida
P4
Unknown30Open-labelAmphotericine in liposome (Ambisome®)
NCT03549312
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
HIV-1-infection, Hepatitis C, Chronic
P4
Unknown25Open-labelGenvoya, Epclusa, Biktarvy
NCT01448616
Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding
Herpes Simplex Type II
P4
Completed73RCT, Double-blindTDF, Placebo Vaginal Gel, Vaginal TFV Gel, Placebo Tablets
NCT00724711
Safety and Efficacy Study of Switching From Epzicom to Truvada
HIV Infection
P4
Completed312RCT, Open-labelemtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC)
NCT00224458
Combination of Efavirenz and Truvada - COMET Study
HIV Infections
P4
Completed400Open-labelTruvada, efavirenz
NCT00644332
An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)
Chronic Angina
P4
Completed172Open-labelRanolazine
NCT04538040
Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine
HIV-1-infection
P4
Completed20Open-labelBictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch
NCT04551573
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
Tuberculosis, Hiv
P4
Withdrawn—RCT, Open-labelRifapentine daily, Rifapentine weekly
NCT01334203
A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)
Angina Pectoris, Coronary Artery Disease
P4
Withdrawn—RCT, Double-blindRanolazine
NCT00444379
Anti-Retrovirals for Kaposi's Sarcoma
Kaposi's Sarcoma, HIV Infections
P4
Completed224RCT, Single-blindLopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
NCT01338636
An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)
Exercise-induced Pulmonary Arterial Hypertension
P4
Completed30Open-labelAmbrisentan
NCT03696290
Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis
Bronchiectasis Adult
P4
Terminated34RCT, Double-blindAztreonam lysine
NCT03032666
Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial
Thalassemia, Hepatitis C
P4
Completed7Open-labelsofosbuvir/velpatasvir
NCT01522625
Tenofovir in Chronic Hepatitis B With Mild ALT Elevation
Chronic Hepatitis B
P4
Completed160RCT, Double-blindtenofovir disoproxil fumarate 300mg per day, Placebo
NCT05147740
Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age
HIV-1-infection
P4
Unknown50Open-labelB/F/TAF
NCT00775606
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
Acquired Immune Deficiency Syndrome
P4
Terminated15RCT, Open-labelLopinavir 400 mg/ritonavir 100 mg, Efavirenz
NCT00224445
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
HIV Infections
P4
Completed100Open-labelTruvada, Atazanavir, Ritonavir
NCT06830668
Same-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation
HIV Infection, HIV
P4
Not Yet Recruiting250Open-labelRegimen:BIC+FTC+TAF
NCT01214759
Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
HIV
P4
Completed103Open-labelTruvada, Raltegravir
NCT02283060
Sleep and Cognition After Atripla to Stribild Switch
HIV
P4
Unknown30RCT, Open-labelStribild, Atripla
NCT02128542
Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis
Hepatitis C Virus Infection
P4
Completed66Open-labelSofosbuvir, RBV
NCT00840463
Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
P4
Terminated4RCT, Double-blindAmbrisentan
NCT07560046
Combating Related Epidemics in HCV
HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV)
P4
Not Yet Recruiting1,280RCT, Open-labelSofosbuvir / Velpatasvir Oral Tablet [Epclusa]
NCT02829034
Targeting Right Ventricle in Pulmonary Hypertension Gilead
Pulmonary Hypertension
P4
Completed22RCT, Double-blindRanolazine, Placebo
NCT02052011
Ranolazine and Microvascular Angina by PET in the Emergency Department
Microvascular Angina
P4
Completed31RCT, Double-blindRanolazine, Placebo
NCT04965662
The Role of Home Packs of HIV PEPSE in High Risk Individuals
HIV-1-infection
P4
Completed139RCT, Open-labelMaraviroc, Truvada
NCT01051960
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
Systemic Sclerosis, Shortness of Breath
P4
Completed12Open-labelAmbrisentan
NCT04944654
Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH
Human Immunodeficiency Virus
P4
Terminated1Open-labelBIKTARVY 50Mg-200Mg-25Mg Tablet
NCT04530630
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant
HIV Infections, Renal Transplant Rejection
P4
Completed20Open-labelBIC/F/TAF 50Mg-200Mg-25Mg Tablet
NCT00386997
ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia
Fungal Infection
P4
Terminated20Open-labelliposomal amphotericin B (AmBisome®)
NCT02529059
SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
HIV
P4
Completed40Open-labelEviplera
NCT00365612
Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients
HIV Infections
P4
Completed300RCT, Open-labelEfavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)
NCT02957864
Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide
Renal Insufficiency,Chronic, Hiv
P4
Unknown80RCT, Open-labeltenofovir alafenamide, abacavir
NCT02246998
Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
HIV-1 Infection
P4
Completed72RCT, Open-labelSTB, TVD, ATR, RTV, ATV, ABC/3TC, Iohexol
NCT02253394
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
Pulmonary Arterial Hypertension
P4
Terminated2RCT, Double-blindAmbrisentan plus Spironolactone, Ambrisentan plus Placebo
NCT00230477
Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT
Hepatitis B
P4
Completed19RCT, Open-labelHepsera, Hepsera and lamivudine
NCT03987503
The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study
Hepatitis C, Chronic
P4
Completed87Open-labelEpclusa (SOF/VEL), Standard of care
NCT02149888
PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5
HIV, Human Immunodeficiency Virus
P4
Completed52Open-labelTenofovir/emtricitabine
NCT00670657
CRITIC - Treatment of Candidemia and Invasive Candidiasis
Candidemia, Invasive Candidiasis
P4
Completed39Open-labelAmBisome
NCT05528653
Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"
HIV Prevention
P4
Completed75Open-labelDescovy
NCT00832572
Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy
Coronary Artery Disease, Pain
P4
Terminated5RCT, Double-blindRanolazine, Placebo
NCT03471624
Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
Hepatitis B, Chronic
P4
Completed270Open-labelTenofovir Alafenamide
NCT02133352
Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction
Pulmonary Hypertension, Diastolic Left Ventricular Dysfunction
P4
Completed10Open-labelRanolazine
NCT03532425
B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults
HIV-1-infection
P4
Terminated28RCT, Double-blindB/F/TAF, Atripla, B/F/TAF Placebo, Atripla Placebo
NCT00615745
ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla
HIV Infections
P4
Completed115Open-labelAtripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
NCT00389194
PREventing Progression of Adipose Tissue Redistribution
HIV Infections
P4
Completed120RCT, Open-labelcontinuing AZT+3TC or switching AZT+3TC to TDF+ FTC
NCT05243602
BFTAF Elderly Switch Study
HIV-1-infection
P4
Completed520RCT, Open-labelSwitch to B/F/TAF, Continue current regimen
NCT03350672
Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide
Hiv
P4
Completed37Open-labelFTC/TAF
NCT00192595
Tenofovir in HIV/HBV Coinfection
HIV Infection, Hepatitis B Coinfection
P4
Completed36RCT, Open-labelTenofovir, Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)
NCT02739360
Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
Lymphoid Malignancies
P4
Terminated3Open-labelIdelalisib
NCT07908446
Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV
HIV-1 Infection
P4
Not Yet Recruiting400RCT, Open-labelBIC/LEN FDC, Lenacapavir, SBR
NCT01761643
CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
Patient Adherence, HIV Seronegativity
P4
Completed398RCT, Open-label—
NCT06525389
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Talaromycosis
P3
Not Yet Recruiting428RCT, Double-blindLiposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill, Deoxycholate Amphotericin B (DAmB)
NCT02344290
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
HIV, Cardiovascular Diseases
P3
Completed7,769RCT, Double-blindPitavastatin, Placebo
NCT04843761
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
Covid19
P3
Completed473RCT, Double-blindRemdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid
NCT00208299
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Coronary Artery Disease
P3
Completed1,231RCT, Double-blindRegadenoson, Adenosine
NCT00208312
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Coronary Artery Disease
P3
Completed787RCT, Double-blindRegadenoson, Adenosine
NCT05568095
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
Advanced Upper Gastrointestinal Tract Adenocarcinoma
P3
Completed1,040RCT, Open-labelDomvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
NCT00757237
Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa
Cystic Fibrosis
P3
Completed274RCT, Open-labelAztreonam for Inhalation Solution (AZLI), Tobramycin Inhalation Solution (TIS)
NCT01872988
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
Chronic Hepatitis B, Hepatocellular Carcinoma
P3
Terminated320RCT, Double-blindTenofovir, Placebo
NCT00823342
ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy
HBe Negative Chronic Hepatitis B, Hepatitis B Viral Infection
P3
Terminated150RCT, Double-blindCLEVUDINE + TENOFOVIR PLACEBO, CLEVUDINE IN ASSOCIATION TENOFOVIR, TENOFOVIR + CLEVUDINE PLACEBO
NCT03852719
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)
Chronic Hepatitis Delta
P3
Completed150RCT, Open-labelBulevirtide
NCT00071201
Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B
Chronic Hepatitis B
P3
Completed48Open-labelAdefovir Dipivoxil for oral suspension, 2 mg/mL
NCT06060665
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
Primary Biliary Cholangitis
P3
Completed96RCT, Double-blindSeladelpar 10 mg, Placebo
NCT01313624
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
Bronchiectasis
P3
Completed266RCT, Double-blindAZLI, Placebo
NCT03901339
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer
Metastatic Breast Cancer
P3
Completed543RCT, Open-labelSacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
NCT01854775
Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
P2P3
Completed129Open-labelE/C/F/TAF, E/C/F/TAF (Low Dose)
NCT01095796
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
HIV, HIV Infections
P3
Completed707RCT, Double-blindStribild, Atripla, Stribild Placebo, Atripla Placebo
NCT01967940
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
HIV, HIV Infections
P3
Completed55RCT, Double-blindTAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
NCT03547908
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults
HIV-1/HBV Co-Infection
P3
Completed244RCT, Double-blindB/F/TAF, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Placebo to match B/F/TAF
NCT02889796
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Rheumatoid Arthritis
P3
Completed1,759RCT, Double-blindFilgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX
NCT01108510
Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
HIV, HIV Infections
P3
Completed698RCT, Double-blindCOBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo
NCT00528957
Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children
HIV Infections
P3
Completed97RCT, Open-labelTenofovir DF, Zidovudine, Stavudine
NCT01033760
Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)
HIV-1 Infections
P3
Completed90RCT, Open-labelraltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine, darunavir; ritonavir; emtricitabine/tenofovir
NCT01314716
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
Bronchiectasis
P3
Completed274RCT, Double-blindAZLI, Placebo
NCT02480712
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Hepatitis C Virus Infection
P3
Completed107Open-labelSOF/VEL
NCT04745351
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
COVID-19
P3
Terminated249RCT, Double-blindRemdesivir, RDV Placebo, Standard of Care
NCT04313881
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndromes
P3
Terminated539RCT, Double-blindMagrolimab, Azacitidine, Placebo
NCT01352416
Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery
Heart; Dysfunction Postoperative, Cardiac Surgery
P3
Terminated15RCT, Double-blindRanolazine, Placebo
NCT02300558
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
Long QT Syndrome Type 3
P3
Terminated41Single-blindEleclazine, Eleclazine placebo
NCT01838590
Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
Hepatitis C Virus
P3
Completed103RCT, Open-labelSOF, RBV
NCT02616783
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
HIV-1 Infection
P3
Completed167RCT, Open-labelE/C/F/TAF, TDF, FTC, FTC/TDF, 3TC, Third agent
NCT02616029
Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
HIV-1 Infection
P3
Completed66RCT, Open-labelE/C/F/TAF
NCT01682720
Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Hepatitis C
P3
Completed421RCT, Double-blindSOF, RBV, Placebo to match SOF, Placebo to match RBV
NCT02671500
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV
Hepatitis C Virus Infection
P3
Completed375Open-labelSOF/VEL
NCT00323544
SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection
HIV Infections
P3
Completed220RCT, Open-labelzidovudine and lamivudine (Combivir®), emtricitabine and tenofovir DF
NCT04292899
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
COVID-19
P3
Completed4,891RCT, Open-labelRemdesivir, Standard of Care
NCT01667731
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
Hepatitis C, Human Immunodeficiency Virus
P3
Completed224Open-labelSOF, RBV
NCT02600819
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis
HIV-1 Infection
P3
Completed55Open-labelE/C/F/TAF, B/F/TAF
NCT01363011
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Acquired Immunodeficiency Syndrome, HIV Infections
P3
Completed106Open-labelE/C/F/TDF, COBI, ATV, DRV, NRTI
NCT00777920
Study of Ambrisentan in Participants With Pulmonary Hypertension
Pulmonary Hypertension
P3
Completed140Open-labelAmbrisentan
NCT01691768
Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services
HIV
P2P3
Completed372RCT, Open-label1% tenofovir gel
NCT02472886
Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection
Hepatitis C Virus Infection
P3
Completed153Open-labelLDV/SOF, RBV
NCT02660905
HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
Human Immunodeficiency Virus, Hepatitis C, Chronic
P3
Completed25Open-labelE/C/F/TAF;, Ledipasvir-Sofosbuvir
NCT04527991
Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Locally Advanced or Metastatic Unresectable Urothelial Cancer
P3
Completed711RCT, Open-labelSacituzumab Govitecan-hziy, Paclitaxel, Docetaxel, Vinflunine
NCT00158821
Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.
HIV Infections
P3
Completed180Open-labelViread (tenofovir disoproxil fumarate), Sustiva (Efavirenz), Epivir (Lamivudine), Zerit (Stavudine) Placebo
NCT00353574
DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
Hypertension
P3
Terminated282RCT, Double-blindDarusentan
NCT01252940
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
HIV-1 Infection
P3
Completed482RCT, Open-labelFTC/RPV/TDF, PI, RTV, NRTIs
NCT01701401
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
Chronic Hepatitis C Virus
P3
Completed870RCT, Open-labelLDV/SOF, RBV
NCT05090410
Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
Rheumatoid Arthritis, JAK Inhibitor
P3
Unknown400RCT, Open-labelfilgotinib 200mg/day, subcutaneous tocilizumab 162mg/biweekly
NCT04409262
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
COVID-19 Pneumonia
P3
Completed649RCT, Double-blindRemdesivir, Tocilizumab, Placebo
NCT02738333
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
Hepatitis C Virus Infection
P3
Completed239RCT, Open-labelLDV/SOF, SOF, RBV
NCT01910636
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection
Hepatitis C
P3
Completed153Open-labelSofosbuvir, RBV
NCT01174173
Ranolazine and Pulmonary Hypertension
Angina, Pulmonary Arterial Hypertension
P3
Completed11Open-labelRanolazine
NCT03696160
The Late Presenter Treatment Optimisation Study
HIV/AIDS
P3
Completed447RCT, Open-labelBiktarvy, Symtuza
NCT00104520
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
Cystic Fibrosis
P3
Completed211RCT, Double-blindAZLI 75 mg two times a day (BID)/three times a day (TID), Placebo two times a day (BID)/three times a day (TID)
NCT01896193
Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection
Hepatitis C
P3
Completed127RCT, Open-labelSOF, RBV
NCT01980875
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
P3
Terminated57RCT, Open-labelIdelalisib, Chlorambucil, Obinutuzumab
NCT02842086
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
Pre-Exposure Prophylaxis of HIV-1 Infection
P3
Terminated5,399RCT, Double-blindF/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo
NCT04112303
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
Hepatitis C Virus Infection
P3
Completed37Open-labelSOF/VEL
NCT01539512
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
P3
Completed220RCT, Double-blindIdelalisib, Rituximab, Placebo to match idelalisib
NCT02201901
Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Hepatitis C Virus Infection
P3
Completed268RCT, Open-labelSOF/VEL, RBV
NCT00091429
Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine
Angina
P3
Completed500RCT, Double-blindRanolazine
NCT01768286
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection
Chronic Hepatitis C Virus
P3
Completed441RCT, Open-labelLDV/SOF, RBV
NCT00712166
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa
Cystic Fibrosis, Lung Infection
P3
Completed160RCT, Double-blindAZLI 75 mg three times daily (TID), Placebo three times daily (TID)
NCT02825212
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
Hepatitis C, Cryoglobulinemia
P2P3
Completed10Open-labelHarvoni, Epclusa
NCT02603120
Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed
HIV-1 Infection
P3
Completed567RCT, Double-blindABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
NCT07178730
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
Breast Cancer, Triple-negative Breast Cancer
P3
Not Yet Recruiting765RCT, Open-labelSacituzumab govitecan, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA], SoC Chemotherapy
NCT00111150
Botswana Tenofovir Oral HIV Prophylaxis Trial
HIV Infection
P2P3
Terminated1,200RCT, Double-blindTenofovir Disoproxil Fumarate 300 mg daily
NCT03110380
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed
HIV-1-infection
P3
Completed567RCT, Double-blindB/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo
NCT01815736
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
HIV, HIV Infections
P3
Completed1,443RCT, Open-labelE/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI
NCT01259713
Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia
Invasive Fungal Disease
P3
Completed355RCT, Double-blindLiposomal amphotericin B, Placebo
NCT04653194
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
Human Immunodeficiency Virus
P3
Completed36RCT, Open-labelBiktarvy, Symtuza
NCT01818596
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
HIV, HIV Infections
P3
Completed252Open-labelE/C/F/TAF
NCT03025308
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
Rheumatoid Arthritis
P3
Completed2,731RCT, Open-labelFilgotinib, Placebo to match filgotinib
NCT01641822
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
Cystic Fibrosis
P3
Completed107RCT, Double-blindAZLI, Placebo to match AZLI, Tobramycin inhalation solution
NCT02469246
Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC
HIV-1 Infection
P3
Completed567RCT, Double-blindF/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent
NCT01106586
Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
HIV, HIV Infections
P3
Completed708RCT, Double-blindStribild, ATV, Ritonavir, FTC/TDF, Stribild Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo
NCT01732913
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Indolent Non-Hodgkin's Lymphomas
P3
Terminated295RCT, Double-blindPlacebo, Rituximab, Idelalisib
NCT01542788
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
Chronic Hepatitis C
P3
Completed278RCT, Double-blindSOF, RBV, Placebo to match SOF, Placebo to match RBV
NCT00811954
Comparative Study of Three NNRTI-Sparing HAART Regimens
HIV Infection
P3
Completed1,814RCT, Open-labelEmtricitabine/tenofovir disoproxil fumarate, Raltegravir, Darunavir, Ritonavir, Atazanavir
NCT00928187
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
HIV, HIV Infections
P3
Completed454RCT, Open-labelemtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line), abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line), emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
NCT01732926
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Indolent Non-Hodgkin's Lymphomas
P3
Terminated475RCT, Double-blindIdelalisib, Rituximab, Bendamustine, Placebo
NCT00578786
A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
Pulmonary Arterial Hypertension
P3
Completed383RCT, Double-blindambrisentan
NCT03631732
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
HIV-1 Infection
P3
Completed496RCT, Open-labelB/F/TAF, NRTIs, Third Agent
NCT02886728
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
Rheumatoid Arthritis
P3
Completed1,252RCT, Double-blindFilgotinib, Placebo to match filgotinib, MTX, Placebo to match MTX
NCT02639338
Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
Hepatitis C Virus Infection
P3
Completed220RCT, Open-labelSOF/VEL/VOX, SOF/VEL
NCT05715528
Study of Obeldesivir in Nonhospitalized Participants With COVID-19
COVID-19
P3
Completed2,011RCT, Double-blindObeldesivir, Obeldesivir Placebo
NCT04115839
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
Psoriatic Arthritis
P3
Terminated106RCT, Double-blindFilgotinib, Placebo to match filgotinib
NCT01940341
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen
HBeAg-negative Chronic Hepatitis B
P3
Completed426RCT, Double-blindTAF, TDF, TAF Placebo, TDF Placebo
NCT00495651
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
HIV Infections, Tuberculosis
P3
Completed2,073RCT, Open-labelAntiretroviral medications, Antiretroviral medications+Isoniazid prophylaxis, Antiretroviral medications, Antiretroviral medications+Isoniazid prophylaxis
NCT02597166
Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection
Hepatitis C, Chronic, Cirrhosis, Decompensated
P3
Completed14Open-labelLedipasvir/Sofosbuvir
NCT07887672
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma
Newly Diagnosed Multiple Myeloma
P3
Not Yet Recruiting600RCT, Open-labelAnitocabtagene autoleucel, Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Fludarabine, Cyclophosphamide
NCT02605954
Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
HIV-1 Infection
P3
Completed275RCT, Open-labelE/C/F/TAF, ABC/3TC, Third Antiretroviral Agent
NCT02487030
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection
Hepatitis C Virus Infection
P3
Completed255RCT, Open-labelLDV/SOF, RBV
NCT05079230
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
Acute Myeloid Leukemia
P3
Terminated378RCT, Double-blindMagrolimab, Venetoclax, Azacitidine, Placebo
NCT00158730
Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment
Invasive Aspergillosis, Other Fungal Infections
P3
Completed800RCT, Double-blindAmBisome
NCT00423748
Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
P3
Completed186RCT, Double-blindambrisentan
NCT02545504
Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
P3
Completed432RCT, Double-blindAndecaliximab, Placebo, Leucovorin, 5-fluorouracil, Oxaliplatin
NCT00051285
ESSENTIAL-"The Studies of Oral Enoximone Therapy in Advanced Heart Failure"
Heart Failure, Congestive
P3
Terminated1,800RCT, Double-blindEnoximone, Enoximone placebo
NCT01442038
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Coronary Artery Disease, Angina Pectoris
P3
Completed2,651RCT, Double-blindRanolazine, Placebo
NCT00003338
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
Lymphoma
P2P3
Unknown60——
NCT02104700
Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
HIV
P2P3
Completed150RCT, Open-labelRilpivirine/Emtricitabine/Tenofovir
NCT01956812
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer, Pancreatic Cancer
P3
Terminated334RCT, Double-blindIMMU-107, placebo, Gemcitabine
NCT01968551
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
HIV-1, HIV Infections
P3
Completed158RCT, Open-labelE/C/F/TAF, DRV, Baseline DRV- containing ARV regimen
NCT04742491
Pre-Exposure Prophylaxis for Transgender Women in the US and South America
HIV Prevention
P2P3
Completed304RCT, Open-labelImmediate Intervention Arm, Deferred Intervention Arm
NCT03602560
ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Primary Biliary Cholangitis
P3
Completed265RCT, Double-blindseladelpar 5-10 mg, seladelpar 10 mg, Placebo
NCT07658976
Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy
HIV Infection, Sexually Transmitted Infection
P3
Not Yet Recruiting400RCT, Open-labelHIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP
NCT03512418
Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)
HIV Infections, Substance Use Disorders
P3
Completed30RCT, Open-labelTruvada
NCT04736173
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
P2
Completed169RCT, Open-labelDomvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
NCT03869190
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Urothelial Carcinoma, Bladder Cancer
P1P2
Terminated272RCT, Open-labelAtezolizumab, Enfortumab Vedotin, Niraparib, Magrolimab (Hu5F9-G4), Tiragolumab, Sacituzumab Govitecan, Tocilizumab, Cisplatin, Gemcitabine
NCT04381832
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms
P1P2
Completed173RCT, Open-labelEtrumadenant, Zimberelimab, Quemliclustat, Enzalutamide, Docetaxel, SG
NCT05329766
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Gastrointestinal Tract Malignancies
P2
Completed332RCT, Open-labelDomvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
NCT00419770
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Mucormycosis
P2
Completed20RCT, Double-blinddeferasirox, Placebo, Liposomal amphotericin B
NCT04891770
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
Chronic Hepatitis B
P2
Completed103RCT, Open-labelTenofovir Alafenamide, VIR-2218, Nivolumab, Selgantolimod
NCT02745535
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
Chronic Hepatitis C
P2
Completed77Open-labelSofosbuvir/Velpatasvir/Voxilaprevir
NCT04262856
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
P2
Completed151RCT, Open-labelDomvanalimab, Etrumadenant, Zimberelimab
NCT03074786
Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH)
HIV-1-infection
P2
Withdrawn—RCT, Open-labelDapivirine, Truvada
NCT01887353
The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure
Atrial Fibrillation, Heart Failure
P2
Terminated8RCT, Double-blindRanolazine, Placebo
NCT04660812
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
Metastatic Colorectal Cancer
P1P2
Completed227RCT, Single-blindAB680, Etrumadenant, Zimberelimab, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib
NCT01067443
Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa
Primary Visceral Leishmaniasis
P2
Completed151RCT, Open-labelLiposomal amphotericin B (AmBisome®) and sodium stibogluconate, Liposomal amphotericin B + miltefosine, Miltefosine
NCT01055847
Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection
Cystic Fibrosis, CF
P2
Completed105RCT, Double-blindAztreonam for Inhalation (AI), Placebo
NCT03434353
Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)
Chronic Hepatitis B
P2
Terminated123RCT, Open-labelInarigivir Soproxil, TAF
NCT06631365
PrEPsmart 2-1-1 Pilot
HIV-1-infection
P2
Unknown60RCT, Open-labelTruvada
NCT02926833
Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Refractory Diffuse Large B Cell Lymphoma
P1P2
Completed37Open-labelKTE-C19, Atezolizumab, Cyclophosphamide, Fludarabine
NCT01435044
Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
Hepatitis C, Chronic
P2
Completed239RCT, Double-blindSofosbuvir, GS-0938, RBV, Placebo to match sofosbuvir, Placebo to match GS-0938
NCT02300103
Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study
Hepatitis C Virus Infection
P2
Completed69Open-labelSOF/VEL, RBV
NCT02258529
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Follicular Lymphoma, Small Lymphocytic Lymphoma
P2
Terminated10Open-labelIdelalisib, Rituximab
NCT04130919
Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
P2
Terminated19RCT, Double-blindTilpisertib, Placebo
NCT01054729
Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients
Hepatitis C
P2
Completed64RCT, Double-blindSofosbuvir, Placebo, PEG, RBV
NCT02249182
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
Hepatitis C Virus Infection
P2
Completed226Open-labelLDV/SOF, RBV
NCT03046056
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
Small Bowel Crohn's Disease
P2
Completed78RCT, Double-blindFilgotinib, Placebo to match filgotinib
NCT04364035
Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients
HIV/AIDS
P2
Completed50RCT, Double-blindChAdOx1.HTI, MVA.HTI, GS-9620, Placebo, Placebo Oral Tablet
NCT00423592
Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension
Pulmonary Hypertension
P2
Completed36Open-labelambrisentan
NCT01334567
Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan
Hepatitis B
P2
Completed30Open-labelTenofovir DF
NCT02405442
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease
P2
Terminated187RCT, Double-blindAndecaliximab, Placebo
NCT01858766
Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection
Hepatitis C
P2
Completed379RCT, Open-labelSOF, VEL, RBV
NCT01730612
ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA
HER2 Negative Breast Carcinoma Expressing CEA
P1P2
Completed23Open-labelTF2 - 68 Ga-IMP-288:
NCT01687257
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Hepatitis C, Cirrhosis
P2
Completed50RCT, Open-labelSOF, RBV
NCT02536313
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen
Hepatitis C Virus Infection
P2
Completed49RCT, Open-labelSOF/VEL/VOX, RBV
NCT01225380
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Chronic Hepatitis C Infection
P2
Completed324RCT, Double-blindGS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo, Pegasys®, Copegus®
NCT02301936
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease
Hepatitis C Virus Infection
P2
Completed10Open-labelLDV/SOF
NCT06682234
Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease
Filovirus Disease, Postexposure Prophylaxis for Filovirus Disease
P2
Withdrawn—Open-labelobeldesivir
NCT01369498
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Myelofibrosis
P2
Completed54RCT, Open-labelSimtuzumab, Ruxolitinib
NCT02254421
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
Respiratory Syncytial Virus Infection
P2
Completed60RCT, Double-blindPresatovir, Placebo
NCT00832507
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension
P2
Terminated162RCT, Double-blindCicletanine, Cicletanine Placebo
NCT02968563
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
P2
Completed35Open-labelTirabrutinib, Idelalisib, Obinutuzumab
NCT00421525
Phase I/II Study of hLL1 in Multiple Myeloma
Multiple Myeloma, Myeloma, Plasma-Cell
P1P2
Completed25Open-labelmilatuzumab
NCT02219685
Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection
Hepatitis C Virus Infection
P2
Completed40RCT, Double-blindLDV/SOF, Placebo
NCT04075916
A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients
End Stage Renal Disease
P2
Completed201Open-labelEpclusa
NCT01796470
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
P2
Terminated66Open-labelEntospletinib, Idelalisib
NCT00002437
The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
Cytomegalovirus Retinitis, HIV Infections
P2
Completed48—Cidofovir, Probenecid
NCT00507507
A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)
Chronic Hepatitis B
P2
Completed126RCT, Double-blindTenofovir DF, FTC, Placebo
NCT01356160
GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
Hepatitis C, Chronic
P2
Completed351RCT, Double-blindGS-5885, GS-9451, peginterferon alfa-2a, ribavirin tablet, GS-9451 Placebo
NCT01452308
Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis
Liver Fibrosis
P2
Completed20Open-labelSimtuzumab
NCT02579382
Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated
Chronic Hepatitis B
P2
Completed192RCT, Double-blindTDF, Vesatolimod, Placebo
NCT06046482
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Head Neck, Squamous Cell Carcinoma of Head and Neck
P2
Terminated4RCT, Open-labelPembrolizumab, Magrolimab, cetuximab, Docetaxel
NCT04958785
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
P2
Terminated92RCT, Open-labelMagrolimab, Nab-Paclitaxel, Paclitaxel, Sacituzumab Govitecan-hziy
NCT03207815
Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis
Noninfectious Uveitis
P2
Terminated74RCT, Double-blindFilgotinib, Placebo to match filgotinib, Prednisone
NCT02348216
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma
P1P2
Completed307Open-labelAxicabtagene Ciloleucel, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
NCT03036852
Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease
Chronic Hepatitis C
P2
Completed59Open-labelSOF/VEL
NCT03312023
Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection
Hepatitis B
P2
Completed21RCT, Open-labelLedipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Sofosbuvir 400 MG [Sovaldi], Ledipasvir 90 MG
NCT04539262
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
COVID-19
P1P2
Completed156RCT, Double-blindRemdesivir (RDV), Placebo
NCT01479465
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Colorectal Cancer
P2
Terminated266RCT, Double-blindSimtuzumab, Placebo to match SIM, Leucovorin, Irinotecan, Fluorouracil
NCT03201445
Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
Inflammatory Bowel Disease
P2
Terminated139RCT, Double-blindFilgotinib, Placebo, Standard of Care
NCT00547066
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura
P1P2
Terminated48Open-labelveltuzumab
NCT01648205
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
Long QT Syndrome
P2
Completed25Double-blindPlacebo, Ranolazine
NCT01938430
Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
Chronic HCV Infection
P2
Completed339RCT, Open-labelLDV/SOF, RBV
NCT01146808
Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver
Hepatitis B, Liver Transplantation
P1P2
Completed16Open-labelAdefovir dipivoxil and hepatitis B vaccination
NCT01672879
Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH
Liver Fibrosis Due to NASH
P2
Terminated259RCT, Double-blindPlacebo, SIM
NCT04892446
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
P2
Terminated36Open-labelMagrolimab, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib
NCT00445146
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
HIV Infections
P2
Completed192Open-labelEVG, RTV, ARV regimen
NCT01799889
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
P2
Terminated326RCT, Open-labelEntospletinib MM, Entospletinib SDD
NCT00664378
Efficacy Study of CYT997 in Multiple Myeloma
Relapsed and Refractory Multiple Myeloma
P2
Terminated5Open-labelCYT997
NCT01565850
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Acquired Immunodeficiency Syndrome, HIV Infections
P2
Completed153RCT, Double-blindD/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo
NCT02534350
Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection
Respiratory Syncytial Virus (RSV)
P2
Completed61RCT, Double-blindPresatovir, Placebo
NCT01101581
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Non Hodgkin's Lymphoma, NHL
P1P2
Withdrawn—RCT, Open-labelVeltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab
NCT00041639
Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer
Pancreatic Neoplasms
P1P2
Completed75Open-labelhMN14 (labetuzumab)
NCT03761056
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
B-cell Lymphoma
P2
Completed42Open-labelAxicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
NCT02445131
Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)
Chronic Lymphocytic Leucemia
P2
Completed48Open-labelBendamustine, GA101, CAL-101
NCT02378961
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection
Hepatitis C Virus Infection
P2
Completed128Open-labelVOX, SOF/VEL
NCT03615066
Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment
Chronic Hepatitis B
P2
Completed67RCT, Double-blindPlacebo, Selgantolimod, TAF
NCT00002234
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
HIV Infections
P2
Completed25—Efavirenz, Adefovir dipivoxil, Lamivudine, Didanosine
NCT00907764
Stress Echocardiography Study With Regadenoson
Heart Disease, Coronary Artery Disease
P2
Terminated22Open-labelregadenoson
NCT01336686
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
Hyperuricemia, Gout
P2
Completed67RCT, Double-blindArhalofenate, Arhalofenate, Placebo comparator, Colchicine
NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation
Hematopoietic Stem Cell Transplantation, Fungus Diseases
P2
Completed75RCT, Open-labelcaspofungin, liposomal amphotericin B
NCT01769196
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
P2
Terminated544RCT, Double-blindSimtuzumab, Simtuzumab placebo
NCT05520723
Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED
Triple Negative Breast Cancer, Breast Cancer
P2
Completed50Open-labelSacituzumab govitecan, Loperamide, Granulocyte Colony-Stimulating Factor
NCT02010255
Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
Chronic HCV Infection
P2
Completed334RCT, Open-labelLDV/SOF, RBV
NCT05629208
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
Cutaneous Lupus Erythematosus (CLE)
P2
Terminated20RCT, Double-blindEdecesertib, Edecesertib Placebo
NCT01279707
Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)
Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
P1P2
Unknown55Open-labelhumanised monoclonal antibody, veltuzumab, humanised monoclonal antibody epratuzumab, humanised monoclonal antibodies veltuzumab and epratuzumab
NCT06071767
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
HIV-1-infection
P1P2
SUSPENDED36RCT, Double-blindChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, GS-2872, MVA.tHIVconsv4, Placebo
NCT01522651
Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
Atrial Fibrillation
P2
Completed134RCT, Double-blindRanolazine, Dronedarone, Ranolazine placebo, Dronedarone placebo
NCT01826981
Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection
Chronic Hepatitis C
P2
Completed359RCT, Open-labelLDV/SOF, SOF, RBV, Peg-IFN, GS-9669, VEL
NCT03100942
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
Sjogren's Syndrome
P2
Completed152RCT, Double-blindLanraplenib, Filgotinib, Tirabrutinib, Lanraplenib placebo, Filgotinib placebo, Tirabrutinib placebo
NCT01605890
Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients
HIV-2 Infection
P2
Completed30Open-labelemtricitabine / tenofovir disoproxil fumarate / raltegravir .
NCT03987074
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Steatohepatitis
P2
Completed109RCT, Open-labelSemaglutide, Firsocostat, Cilofexor
NCT00869557
Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
HIV, HIV Infections
P2
Completed71RCT, Double-blindStribild, Atripla
NCT02601313
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)
Relapsed/Refractory Mantle Cell Lymphoma
P2
Completed105Open-labelbrexucabtagene autoleucel, Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel
NCT01672853
Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)
Primary Sclerosing Cholangitis (PSC)
P2
Completed235RCT, Double-blindSimtuzumab, Placebo
NCT02166047
Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants
Chronic Hepatitis B
P2
Completed162RCT, Double-blindVesatolimod, Placebo
NCT02759562
Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis
Cystic Fibrosis
P2
Terminated6RCT, Double-blindAndecaliximab, Placebo
NCT00002415
Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients
HIV Infections
P2
Completed175Double-blindTenofovir disoproxil fumarate
NCT02781584
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
P2
Completed220Open-labelSEL, FIR, CILO, FENO, VAS
NCT05165771
Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment
Rheumatoid Arthritis
P2
Withdrawn—RCT, Double-blindGS-5718, GS-5718, Placebo to match GS-5718, Tofacitinib 5 mg, Placebo to match Tofacitinib
NCT00422487
Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
P2
Completed60RCT, Double-blindMBX-2044, MBX-2044, MBX-2044, MBX-2044, MBX-2044, MBX-2044, Placebo for MBX-2044
NCT05459571
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
Relapsed or Refractory Large B-cell Lymphoma
P2
Completed35Open-labelAxicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Dexamethasone
NCT07743541
Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy
Uterine Endometrial Cancer
P1P2
Not Yet Recruiting100Open-labelTUB-040 - Dose escalation, TUB-040 - RP2D
NCT03285711
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
Lupus Membranous Nephropathy
P2
Completed9RCT, Double-blindFilgotinib, Lanraplenib, Filgotinib placebo, Lanraplenib placebo
NCT00334256
Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA)
HIV Infection, Pregnancy
P2
Completed72Open-labelTenofovir (TDF), Emtricitabine (FTC)
NCT00645294
Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV
Hepatitis B
P1P2
Completed47RCT, Open-labelAdefovir dipivoxil, Adefovir Dipivoxil, Adefovir Dipivoxil
NCT00528060
Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada
HIV Infections
P2
Completed35Open-labelAtazanavir, Ritonavir, Tenofovir/emtricitabine
NCT02161679
Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer
Triple-negative Breast Cancer
P2
Withdrawn—RCT, Open-labelIMMU-132 infusion is administered to participants in one arm for the study, IMMU-132 plus Carboplatin infusion
NCT00989586
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Lymphoma
P1P2
Completed35Open-labelmilatuzumab, veltuzumab, veltuzumab and milatuzumab
NCT00499239
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
P1P2
Terminated32Open-labelGS-9219
NCT04778410
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Myeloid Malignancies
P2
Terminated54Open-labelMagrolimab, Azacitidine, Venetoclax, Mitoxantrone, Etoposide, Cytarabine, CC-486
NCT01271790
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Hepatitis C, Chronic
P2
Completed245RCT, Double-blindTegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, GS-9451, Tegobuvir placebo, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo, Pegasys®, Copegus®
NCT00421395
Safety Study of NHL With 90Y-hLL2 IgG
NHL, B-cell NHL
P1P2
Completed59Open-label90Y-hLL2
NCT00507689
Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant
Chronic Hepatitis B
P2
Completed40RCT, Double-blindFTC/TDF, Hepatitis B Immunoglobulin (HBIg)
NCT02994056
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
Hepatitis C Virus Infection
P2
Completed32Open-labelSOF/VEL, RBV
NCT01497899
Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Acquired Immunodeficiency Syndrome, HIV Infections
P2
Completed279RCT, Double-blindE/C/F/TDF, E/C/F/TAF Placebo, E/C/F/TAF, E/C/F/TDF Placebo
NCT03472950
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis
ALS
P2
Completed14Open-labelRanolazine 500 MG, Ranolazine 1000 MG
NCT00002219
Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children
HIV Infections
P2
Unknown36—Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil
NCT06250036
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer
P2
SUSPENDED50RCT, Open-labelSingle agent zimberelimab, Combination zimberelimab + domvanalimab
NCT01399008
Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients
Gout
P2
Completed100RCT, Double-blindArhalofenate, Allopurinol, Colchicine, Placebo
NCT02568683
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Non-Hodgkin Lymphoma
P1P2
Terminated10Open-labelEntospletinib, Vincristine
NCT05330429
Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
Metastatic Colorectal Cancer
P2
Terminated77RCT, Open-labelMagrolimab, Bevacizumab, Irinotecan, Fluorouracil, Leucovorin
NCT00002184
A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient
HIV Infections
P2
Completed120Double-blindNelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine
NCT00701883
Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol
Hyperlipidemia
P2
Completed183RCT, Double-blindPlacebo, MBX-8025, MBX-8025, Atorvastatin, MBX-8025, MBX-8025
NCT01987453
Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
HCV Infection
P2
Completed100Open-labelLDV/SOF, RBV
NCT01282424
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
Follicular Lymphoma, Small Lymphocytic Lymphoma
P2
Completed125Open-labelIdelalisib
NCT03491553
Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B
Chronic Hepatitis B
P2
Completed48RCT, Double-blindSelgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy
NCT00298363
Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.
Chronic Hepatitis B
P2
Completed112RCT, Double-blindTenofovir disoproxil fumarate (tenofovir DF; TDF), Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), Entecavir (ETV), TDF placebo, FTC/TDF placebo, ETV placebo
NCT00546793
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
NHL, Lymphoma, Non-Hodgkin
P1P2
Completed32Open-labelveltuzumab
NCT02466516
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
Non-Alcoholic Steatohepatitis (NASH)
P2
Completed72RCT, Open-labelSEL, SIM
NCT02226549
Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis
Hepatitis C Virus Infection
P2
Completed47RCT, Open-labelLDV/SOF, VDV, RBV
NCT01559844
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Hepatitis C, Hepatocellular Carcinoma
P2
Completed61Open-labelSofosbuvir, Ribavirin
NCT02885181
Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate
Rheumatoid Arthritis
P2
Completed83RCT, Double-blindGS-9876, Filgotinib, GS-9876 placebo, Filgotinib placebo, Methotrexate
NCT00270556
Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.
HIV
P2
Completed100—tenofovir disoproxil fumarate, Abacavir
NCT01687270
Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant
Recurrent Chronic Hepatitis C Virus, Post Liver Transplant
P2
Completed40Open-labelSofosbuvir, RBV
NCT00725803
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV
HCV Infection
P2
Completed33RCT, Double-blindGS-9450, GS-9450 Placebo
NCT06123468
Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma
Esophagogastric Adenocarcinoma
P1P2
Completed58Open-labelSacituzumab govitecan
NCT00936715
Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States
Chronic Hepatitis B
P2
Completed24Open-labelFTC/TDF
NCT06585150
Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
RSV Infection
P2
Terminated150RCT, Double-blindObeldesivir, Obeldesivir Placebo
NCT02862548
Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant
Chronic Hepatitis B
P2
Completed51RCT, Open-labelTAF, TDF, Other approved antivirals
NCT01659047
A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
P2
Withdrawn—Open-labelGS-1101
NCT01838434
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Relapsed/Refractory Mantle Cell Lymphoma
P1
Completed106RCT, Open-labellenalidomide, idelalisib
NCT04087018
Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
Advanced Solid Tumors
P1
Completed18Open-labelzimberelimab
NCT05277012
A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants
Healthy Participants
P1
Completed24RCT, Open-labelEtrumadenant
NCT03846310
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer
P1
Completed77Open-labelEtrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
NCT05411146
A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer
Healthy Participants
P1
Completed8Open-label[14C]-etrumadenant
NCT04314843
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
Relapsed/Refractory Large B-cell Lymphoma
P1
Terminated6Open-labelCyclophosphamide, Fludarabine, Lenzilumab, Axicabtagene Ciloleucel
NCT00561496
Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel
HIV Infections
P1
Completed49Open-labelTenofovir gel
NCT03628677
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
Solid Tumor, Unspecified, Adult
P1
Completed75Open-labelDomvanalimab, Zimberelimab
NCT04772989
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC)
P1
Completed94Open-labelAB308, Zimberelimab
NCT01779505
A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults
Healthy Volunteers
P1
Completed60RCT, Open-labelGS-4774
NCT01845740
Phase Ib Study of SC Milatuzumab in SLE
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid
P1
Completed22RCT, Double-blindmilatuzumab, Placebo
NCT01847391
A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects
Ischemic Heart Disease
P1
Completed36RCT, Single-blindGS-6615, Placebo
NCT00002396
The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients
HIV Infections
P1
Unknown60Double-blindTenofovir disoproxil fumarate
NCT03135028
Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults
Hematologic Malignancy, Acute Myeloid Leukemia
P1
Terminated9Open-labelEntospletinib, Daunorubicin, Cytarabine
NCT02533427
Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
HCV Infection
P1
Completed15Open-labelSOF/VEL/VOX, VOX, Norgestimate/ethinyl estradiol
NCT01675973
A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine
Severe Renal Impairment
P1
Terminated4Open-labelRANEXA
NCT00041691
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery
Colorectal Neoplasms
P1
Terminated30Open-labelhMN14 (labetuzumab)
NCT01849003
Study of the Effect of GS-6615 in Subjects With LQT-3
Long QT Syndrome
P1
Completed24Open-labelGS-6615
NCT02876796
Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects
PD Effects of GS-0976 (NDI-010976) on Fractional DNL
P1
Completed30RCT, Double-blindGS-0976, Placebo
NCT00185081
Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging
Colonic Neoplasms
P1
Completed42Open-labelIndium labeled IMP-205xm734
NCT04382404
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir
Hepatitis C, Chronic
P1
Completed11Open-labelSofosbuvir-Velpatasvir Drug Combination
NCT02521376
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
Oncology
P1
Completed56Open-labelEntospletinib
NCT02258555
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
Follicular Lymphoma, Chronic Lymphocytic Leukemia
P1
Terminated7Open-labelGS-9901
NCT01740791
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection
Chronic Hepatitis C Virus
P1
Completed103RCT, Double-blindVelpatasvir, Placebo
NCT03399448
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
Multiple Myeloma, Melanoma
P1
Terminated3Open-labelNY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine
NCT01671787
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
Chronic Hepatitis B
P1
Completed51RCT, Open-labelGS-7340, Tenofovir disoproxil fumarate
NCT01801293
A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806
RSV Infection
P1
Completed8Open-labelGS-5806
NCT05770895
Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B
Chronic Hepatitis B
P1
Completed83RCT, Double-blindGS-2829, GS-6779, Placebo
NCT00710528
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL)
P1
Completed192Open-labelCAL-101
NCT07530263
Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)
Chronic Pulmonary Aspergillosis
P1
Not Yet Recruiting18RCT, Open-label12 mg of nebulised 99mTc-liposomal amphotericin B, 24 mg of nebulised 99mTc-liposomal amphotericin B
NCT01797419
Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)
Respiratory Syncytial Virus Infections
P1
Withdrawn—RCT, Double-blindGS-5806, Placebo
NCT01273402
Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
P1
Withdrawn—Open-labelTF2/IMP288
NCT01590641
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Hepatitis B, HBV
P1
Completed49RCT, Double-blindSingle Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts
NCT02251457
Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1
Myotonia Congenita, Paramyotonia Congenita
P1
Completed35Open-labelRanolazine
NCT02002767
Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment
Hepatitis C Virus
P1
Completed19Open-labelVelpatasvir
NCT03151057
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia
P1
Terminated16RCT, Double-blindIdelalisib 100 MG, Placebo Oral Tablet
NCT02712346
The Role of Endothelin-1 in Sickle Cell Disease
Sickle Cell Anemia
P1
Completed26RCT, Double-blindAmbrisentan, Placebo
NCT00002346
The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients
HIV Infections
P1
Completed36Double-blindAdefovir dipivoxil
NCT01817985
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Chronic Hepatitis C
P1
Completed33Open-labelGS-5816
NCT01840735
Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF
Cystic Fibrosis
P1
Completed8RCT, Double-blindGS-5737, Placebo
NCT01793649
A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects
Cystic Fibrosis, Chronic Obstructive Pulmonary Disease
P1
Terminated7RCT, Double-blindGS-5737
NCT05458102
Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
P1
Terminated18Open-labelVesatolimod, Cobicistat, Voriconazole, Rifabutin
NCT04950764
An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Primary Biliary Cholangitis, Compensated Cirrhosis
P1
Completed24Open-labelSeladelpar
NCT02365532
Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
Long QT Syndrome
P1
Completed60RCT, Double-blindGS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide
NCT00800579
Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers
Cystic Fibrosis
P1
Completed12RCT, Double-blindGS-9411, Placebo
NCT01816646
Intravesical Cidofovir for Hemorrhagic Cystitis
Blood And Marrow Transplantation
P1
Completed6Open-labelCidofovir, Probenecid
NCT03139370
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
Solid Tumor
P1
Terminated16Open-labelKITE-718, Cyclophosphamide, Fludarabine
NCT02185794
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
Hepatitis C Virus Infection
P1
Completed101RCT, Double-blindVoxilaprevir, Placebo to match voxilaprevir, SOF/VEL
NCT02402452
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
HCV Infection
P1
Completed20Open-labelVoxilaprevir
NCT02397707
Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
HCV Infection
P1
Completed33Open-labelVoxilaprevir
NCT02296853
Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment
Hepatitis B Virus
P1
Completed20Open-labelTAF
NCT00836914
Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber
Allergic Rhinitis
P1
Completed41RCT, Double-blindCAL-101, Placebo
NCT02392611
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer
Solid Tumors and Lymphomas
P1
Completed33Open-labelAlobresib, Exemestane, Fulvestrant
NCT02678338
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
Acute Myeloid Leukemia, Myelodysplastic Syndrome
P1
Completed20Open-labelHu5F9-G4
NCT07038447
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Systemic Lupus Erythematosus, Lupus Nephritis
P1
By Invite52Open-labelKITE-363, Fludarabine, Cyclophosphamide
NCT00999531
A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers
Cystic Fibrosis, Mucociliary Clearance
P1
Completed24RCT, Double-blindGS-9411, Placebo
NCT02683005
Study of Hepatitis C Treatment During Pregnancy
Hepatitis C, Pregnancy
P1
Completed9Open-labelledipasvir/sofosbuvir
NCT02891408
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
Nonalcoholic Steatohepatitis (NASH)
P1
Completed74Open-labelFirsocostat, Fenofibrate
NCT01705847
A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
Lymphoid Malignancies
P1
Completed39Open-labelGS-9820
NCT03624036
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
P1
Terminated16Open-labelbrexucabtagene autoleucel, Fludarabine, Cyclophosphamide
NCT02203461
Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication
Insulin Resistance
P1
Completed30RCT, Open-labelTenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat, Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir, Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir
NCT02654002
Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics
Nonalcoholic Steatohepatitis (NASH)
P1
Completed120RCT, Double-blindCilofexor, Placebo
NCT01590654
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Hepatitis B
P1
Completed51RCT, Double-blindSingle Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620
NCT02365506
Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome
LQT2 Syndrome
P1
Completed13RCT, Double-blindEleclazine, Placebo
NCT02209987
Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults
Ulcerative Colitis
P1
Completed28RCT, Open-labelGS-5745 SC, GS-5745 IV
NCT05169944
Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
Brain Cancer, Malignant Brain Tumor
P1
Completed13Open-labelMagrolimab
NCT03405194
Same-Day Treatment With Genvoya vs. EFV/TDF/3TC
HIV/AIDS
N/A
Withdrawn—RCT, Open-labelElvitegravir, Cobicistat, TAF, FTC, Efavirenz, TDF, and 3TC
NCT02619604
A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
N/A
Completed50Open-label—
NCT03693040
Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)
HIV Prevention
N/A
Unknown100Open-label—
NCT06585189
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
Metastatic Non Small Cell Lung Cancer
Completed304—Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
NCT01236261
Prospective Population Study on Candidemia in Spain
Fungemia
Completed730——
NCT06607393
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
Metastatic Nonsmall Cell Lung Cancer
Completed851—Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
NCT06607601
CARE Initiative: Real-world Emulation of the PALOMA-2 Trial
Metastatic Breast Cancer
Completed724—Palbociclib, Letrozole
NCT02272062
Patient-Reported Preferences Affecting Revascularization Decisions
Coronary Artery Disease, Angina Pectoris
N/A
Completed203RCT, Double-blind—
NCT04323761
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
SARS-CoV2 Infection
APPROVED_FOR_MARKETING——Remdesivir
NCT02907996
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
Hepatitis C Virus
Completed2,033—Sofosbuvir
NCT00263614
Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.
Chronic Hepatitis B
Completed100——
NCT03498625
Crohn's Disease Endoscopic REmission Definition in an Objective Way
CD
N/A
Completed240Open-label—
NCT03387397
Assessing Differential Adherence to Medications and Quality of Life Among People Living With HIV and Comorbidities
HIV Infection Primary
Completed170——
NCT01767597
Application of HBV Rapid Tests as a Tool for Wide-Use Screening
Hepatitis B, Liver Cirrhosis
N/A
Completed1,000RCT, Open-label—
NCT04354818
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
HIV-1-infection, Cancer
Unknown27——
NCT03607396
Study for Evaluating the Real Use of Inhaled Aztreonam Lysine in Patients With Cystic Fibrosis
Cystic Fibrosis
Unknown75——
NCT01832571
SCOPE: Strategies to Combine PrEP With Prevention Efforts
HIV
N/A
Withdrawn—Open-labelOnce daily Truvada®
NCT03752658
TAF Real World Study for Universal Effectiveness
Chronic Hepatitis b
Unknown500—Tenofovir Alafenamide
NCT00989807
Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
Cystic Fibrosis, Pseudomonas Aeruginosa
APPROVED_FOR_MARKETING——Aztreonam lysine
NCT02110914
A Coaching Intervention to Young Adults With Cystic Fibrosis
Cystic Fibrosis
N/A
Completed40RCT, Open-label—
NCT02687061
Chronic Hepatitis B and C Recall Northern Holland
Hepatitis B, Hepatitis C
Unknown300——
NCT01646541
Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery
Pulmonary Hypertension, Mitral Valve Disease
Completed100——
NCT01072669
Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet
Ischemia
N/A
Completed20RCT, Double-blindambrisentan
NCT03986099
Community Based Antiretroviral Therapy (CBART) Among Children on Chronic ART
ART, HIV I Infection
N/A
Completed451Single-blind—
NCT00158704
Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.
Hepatitis B
N/A
Terminated400Open-labelHepsera
NCT06688149
NASH Patient's Itinerary: Comparison of Strategies for Screening, Referring and Management of Diabetic Patients
Non-alcoholic Fatty Liver Disease (NAFLD)
N/A
Completed536RCT, Open-label—
NCT00905151
HIV and Kidney Function Study
HIV Infections, AIDS
Completed206——
NCT03582098
Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
Chronic Lymphocytic Leukaemia
Completed112—Idelalisib, Rituximab
NCT02167100
Patient Retention in HIV Medical Care in a Primary Care Practice in Australia
HIV
Completed1,537——
NCT04162756
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
Relapse/Refractory Mantle Cell Lymphoma
APPROVED_FOR_MARKETING——Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide
NCT04891445
Hepatitis C in Severe Mental Disorders: Nursing Programme
Hepatitis C, Severe Mental Disorder
N/A
Completed16RCT, Single-blind—
NCT02318524
Clinical Impact of Fungal Domestic Environmental Exposure on COPD Patients
COPD, Pulmonary Fungal Diseases
Completed65——
NCT05520905
TelePrEP for At-risk Youth in Colorado
Hiv
N/A
Unknown100Open-label—
NCT03195205
Identification to Elimination in HCV-Infected Individuals
Hepatitis C
Early P1
Completed3,051Open-label—
NCT03134105
A Wearable EducAtional Intervention to REduce Angina
Angina
N/A
Withdrawn—RCT, Open-label—
NCT02562742
Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
Hepatitis C
Completed554—SOF, REB
NCT02573376
Antiviral Pharmacology and Adherence in Drug Users
HEPATITIS C, Virus, Human Immunodeficiency
N/A
Completed73RCT, Open-label—
NCT01326221
Single Dose Truvada in HIV-negative Men and Women
Pharmacokinetic Study in Healthy Volunteers
Completed12—tenofovir + emtricitabine
NCT01066858
Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding
HIV Infections
Completed1,765—Tenofovir disoproxil fumarate (TDF)
NCT02591277
Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Hepatitis C
Completed3,294—Harvoni
NCT04090151
The RESPOND Outcomes Study
HIV
Unknown37,853——
NCT04582266
PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US
COVID-19
Completed54—Remdesivir
NCT05526118
Advanced HIV: Outcomes for Rapid ART
HIV-1-infection
Unknown50—Bictegravir/emtricitabine/tenofovir alafenamide
NCT01779518
Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C
Post-transplant Hepatitis C
APPROVED_FOR_MARKETING——Sofosbuvir, Ribavirin, Pegylated Interferon
NCT00660361
A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-HBV co-Infected Patients
HIV Infections, Hepatitis B Virus
Unknown92——
NCT07618507
Resistance Profile to Antiretroviral Medications in Individuals Living With HIV Who Failed a First-Line Regimen With Tenofovir / Lamivudina and Dolutegravir in Brasil
HIV, HIV -1 Infection
N/A
Completed777RCT, Open-labelTL+D antiretroviral
NCT02136511
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL)
APPROVED_FOR_MARKETING——Idelalisib, Rituximab
NCT04519970
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
Hiv
N/A
Completed100Open-label—
NCT05776160
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
Large B-cell Lymphoma, Follicular Lymphoma
AVAILABLE——Axicabtagene Ciloleucel
NCT01093885
Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Systemic Sclerosis, Scleroderma
N/A
Completed15Open-labelAmbrisentan
NCT03794791
A Comprehensive HBsAg-positive Patients Centered Screening Strategy
Hepatitis B and Hepatitis C (Disorder)
Completed10,000——
NCT03876470
Conquering Hepatitis C Via Micro-Elimination in Southwest Virginia
Hepatitis C
Unknown300——
NCT02928510
Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma
Absence of Signs or Symptoms, B-Cell Non-Hodgkin Lymphoma
Terminated1—Idelalisib
NCT00499187
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
HIV Infections, Fanconi Syndrome
Completed56——
NCT04756193
Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 With Point of Care Ultrasound
Covid19, Echocardiography
Completed98——
NCT02958358
FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
Pulmonary Arterial Hypertension
N/A
Withdrawn—Open-label—
NCT00002181
Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS
Herpes Simplex, HIV Infections
N/A
Completed—Open-labelCidofovir
NCT05776134
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia
AVAILABLE——Brexucabtagene Autoleucel
NCT04009057
Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
HIV-1-infection
Completed143——
NCT05181956
Testing and Epidemiology of Delta Hepatitis
Chronic Hepatitis D Infection With Hepatitis B
Unknown5,000——
NCT06465862
Development of a Silica Microparticle Taggant System to Measure ART Adherence
Hiv, Medication Adherence
N/A
Withdrawn—Open-labelBiktarvy Pill
NCT02592057
Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India
Hepatitis C Virus
Completed532—SOF
NCT00637429
HIV-HBV Co-Infection and Liver Disease
HIV Infections, HIV-HBV Co-Infection
Unknown70——
NCT04930614
Prevalence and Risk Factors of HIV Infections in Transgender and Non-binary People in Flanders and Brussels (Belgium)
HIV Infections
Completed1,068——
NCT04610762
HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug Users in Brussels
Hepatitis C, Chronic
Completed103——
NCT03627546
HCV Seek, Test and Rapid Treatment for Young PWID
Hepatitis C, Drug Use
N/A
Completed39RCT, Open-label—
NCT03595527
Universal HIV Screening and Targeted HCV Screening in Emergency Department
Hepatitis C, Hiv
N/A
Completed6,350Open-label—
NCT00002142
An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS
Cytomegalovirus Retinitis, HIV Infections
N/A
Completed100Open-labelCidofovir, Probenecid
NCT02951364
Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea
Hepatitis C Virus
Completed1,081—LDV/SOF
NCT02427204
Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality
Hepatitis C Infection
Completed150——
NCT01322932
Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey
HIV Infection
Completed95——
NCT00002384
A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
Cytomegalovirus Retinitis, HIV Infections
N/A
Unknown——Cidofovir
NCT00645736
CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study
Chronic Hepatitis B
Completed788——
NCT03153462
Axicabtagene Ciloleucel Expanded Access Study
Relapsed/Refractory Diffuse Large B Cell Lymphoma, Relapsed/Refractory Primary Mediastinal B Cell Lymphoma
APPROVED_FOR_MARKETING——Axicabtagene Ciloleucel
NCT00002161
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3
HIV Infections
N/A
Completed400Double-blindAdefovir dipivoxil
NCT04847622
Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
Covid19
Completed451—Remdesivir
NCT07385183
CARE: Comprehensive Assessment of Real-world Effectiveness of F/TAF in Persons Who Use Drugs (PWUD)
People Who Inject Drugs, PrEP Adherence
Not Yet Recruiting200——
NCT06897059
Effectiveness of Smartphone Application for Adherence Support (Vuka+)
Adherence, Medication, Smartphone Application
N/A
Completed330RCT, Open-label—
NCT03278990
Scalable Interventions to Increase PrEP Adherence: Value Affirmation and Future Selves
HIV Prevention
N/A
Terminated26RCT, Double-blind—
NCT01754428
Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age
Respiratory Syncytial Virus Infections
Completed2,432——
NCT04226131
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
Rheumatoid Arthritis, Healthy Controls
N/A
Completed21Open-label—
NCT03581383
Community Access, Retention in Care, and Engagement for Hepatitis C Treatment
Hepatitis C
N/A
Completed657RCT, Open-label—
NCT01737047
The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'
HIV Positive, Ageing
Completed1,377——
NCT06539052
MIGrant Reflex Test HDV (MIGRED) Project
Hepatitis D Virus Infection
Not Yet Recruiting7,500——
NCT01319253
A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies
Cystic Fibrosis, Pseudomonas Aeruginosa
Completed27——
NCT03078153
Effect of Social Media Support and Financial Incentives on PrEP Adherence
Pre-Exposure Prophylaxis
N/A
Completed57RCT, Open-label—
NCT05627466
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
NO_LONGER_AVAILABLE——Magrolimab
NCT07390409
ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.
HIV
Not Yet Recruiting3,700—Lenacapavir Injection, Cabotegravir (CAB) LA, Tenofovi-Emtricitabine (TDF/FTC) tablet
NCT02342821
Empowering Immigrants in the Greater Boston Area to Connect to HBV Care
Hepatitis
Unknown100——
NCT03038763
Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers
Hepatitis C, Hepatitis C, Chronic
Completed100——
NCT05095818
Impact of Nursing Involvement on Implementation of HIV Prevention Services
Pre-Exposure Prophylaxis (PrEP)
N/A
Completed440RCT, Double-blind—